GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: AK-117 | AK117
Compound class:
Antibody
Comment: Ligufalimab (AK117) is a humanized IgG4 anti-CD47 antibody [1-2]. In the tumour microenvironment blocking CD47 interaction with its receptor SIRPα enhances M2 macrophage-mediated phagocytosis of CD47-expressing malignant cells from variety of tumour types. Unlike other anti-CD47 antibodies (such as magrolimab) ligufalimab does not induce hemagglutination, so should be devoid of hematotoxic side effects (anemia and thrombocytopenia) due to the expression of CD47 on erythrocytes.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Ligufalimab (AK117) is a clinical candidate immuno-oncology agent for solid tumours and haematological malignancies. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06642792 | A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma | Phase 1/Phase 2 Interventional | Akeso | ||
| NCT06789848 | Ligufalimab and Cadonilimab in Advanced Liver Cancers | Phase 2 Interventional | University of Texas Southwestern Medical Center | ||
| NCT06601335 | A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Phase 3 Interventional | Akeso | ||
| NCT05382442 | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Phase 2 Interventional | Akeso | ||
| NCT05960955 | Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 Interventional | Akeso | ||
| NCT06196203 | A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes | Phase 2 Interventional | Akeso | ||
